Web:AXA/FY25/Activity report/summary
Appearance
AXA Group — Activity report summary
December 31, 2025
Operating highlights
Governance
- Board of Directors proposed the renewal of Thomas Buberl's mandate as director (4-year term) at the 2026 AGM, with intention to reappoint him as CEO.
- April 24, 2025 AGM approved renewal of Guillaume Faury and Ramon Fernandez mandates (4 years each) and ratified co-optation of Ewout Steenbergen. Ramon de Oliveira's term ended.
- Effective December 1, 2025, leadership changes for next strategic cycle:
- Guillaume Borie appointed Global Head of Finance, Strategy, Underwriting, Risk and Technology (replacing Frédéric de Courtois).
- Mathieu Godart appointed CEO of AXA France, joining the Management Committee.
- Karima Silvent appointed Deputy General Secretary (HR, Audit, Compliance, AXA EssentiALL, GIE AXA).
- Matthieu Caillat appointed Group Chief Technology & AI Officer and CEO of AXA Group Operations.
- Ewout Steenbergen appointed Chair of Audit Committee (December 11, 2025), succeeding Isabel Hudson who stepped down December 31, 2025.
Significant transactions
- Nobis Group acquisition (completed April 1, 2025): Upfront consideration €423m with potential earn-out of up to €55m. Solvency II ratio impact: -1 point in Q2 2025.
- Sale of AXA Investment Managers to BNP Paribas (completed July 1, 2025): Cash proceeds of €5.1bn for AXA IM + €0.3bn for Select = €5.4bn total. One-off net income gain of ca. €2.2bn. Expected annualized reduction in Underlying Earnings of ca. €0.4bn. Long-term partnership established for investment management services. AXA retains full authority over product design, asset allocation and asset-liability management decisions. Solvency II ratio impact: ca. +2 points (including associated share buy-back) in Q3 2025.
- Prima acquisition (completed November 28, 2025): Acquired 51% of the leading Italian direct insurance MGA for €0.5bn. Call/put options for remaining stake expected to be exercised in 2029 or 2030. Prima had €1.2bn premiums, ca. 10% Italian retail motor market share, and 90% combined ratio in 2024. Expected to strengthen AXA's position in direct distribution, which generated €3.5bn in premiums for the Group in 2024. Solvency II ratio impact: -3 points at closing + expected -2 points over time from premium recapture.
Capital and debt operations
- €1.2bn share buy-back (Feb–May 2025): Aligned with capital management policy. Completed May 19, 2025. All shares cancelled.
- €3.8bn share buy-back (Jul 2025–Jan 2026): Offset earnings dilution from AXA IM sale. Completed January 19, 2026. Shares being progressively cancelled.
- Shareplan buy-back (Jun–Jun 2025): Up to €724.6m to eliminate dilution from Shareplan 2025 and cover stock-based compensation delivery.
- Shareplan 2025 (Dec 2025): Capital increase of ca. €411m; ca. 13m new shares issued; ca. 42,000 employees in 40 countries (36%+ participation). Post-Shareplan total shares: 2,136,232,264. Employee ownership: 4.82% of capital, 6.61% of voting rights.
- June 2025 debt issuance: €1bn Restricted Tier 1 notes (5.750% fixed until Dec 2030; rated BBB+/Baa1(hyb)) + €1bn Tier 2 notes due 2055 (4.375% fixed until Jul 2035; rated A-/A2(hyb)). Both include loss absorption mechanisms under Solvency II.
- October 2025 debt issuance: €750m Restricted Tier 1 notes (5.125% fixed until Mar 2032; rated BBB+/A3(hyb)) + €750m Tier 2 notes due 2056 (4.125% fixed until Jul 2036; rated A-/A1(hyb)).
Events subsequent to December 31, 2025
- €1.25bn share buy-back approved by Board (Feb 25, 2026): Expected to commence as soon as practicable and complete by year-end. All shares to be cancelled.
Market environment
Stock markets
| Index | Dec 31, 2025 | YoY change 2025 | Dec 31, 2024 | YoY change 2024 |
|---|---|---|---|---|
| CAC 40 | 8,150 | +10% | 7,381 | -2% |
| Eurostoxx 50 | 5,791 | +18% | 4,896 | +8% |
| FTSE 100 | 9,931 | +22% | 8,173 | +6% |
| Nikkei | 50,339 | +26% | 39,895 | +19% |
| S&P 500 | 6,846 | +16% | 5,882 | +23% |
| MSCI World | 4,430 | +19% | 3,708 | +17% |
| MSCI Emerging | 1,404 | +31% | 1,075 | +5% |
- Global equities delivered another strong year despite geopolitical and macro uncertainties. Disinflation trends, clearer monetary signals, and resilient corporate earnings supported markets.
- US: S&P 500 +16%; tariff-induced volatility peaked in April, then sentiment recovered on resilient growth and easing expectations.
- Europe: Eurostoxx 50 +18% on improved growth outlook; CAC 40 +10% (trailing peers due to fiscal uncertainty); FTSE 100 +22% on attractive valuations.
- Asia: Nikkei +26% driven by global AI boom, weaker yen enhancing export competitiveness, and a U.S.-Japan trade deal; MSCI Emerging +31%.
Bond markets
| Bond | Dec 31, 2025 | YoY change (bps) | Dec 31, 2024 | YoY change (bps) |
|---|---|---|---|---|
| 10Y French bond | 3.56% | +37 | 3.20% | +64 |
| 10Y German bond | 2.86% | +49 | 2.37% | +34 |
| 10Y Swiss bond | 0.32% | -1 | 0.33% | -38 |
| 10Y Italian bond | 3.55% | +3 | 3.52% | -18 |
| 10Y UK bond | 4.48% | -9 | 4.57% | +103 |
| 10Y Japanese bond | 2.07% | +97 | 1.10% | +49 |
| 10Y US bond | 4.17% | -40 | 4.57% | +69 |
- US: Three Fed rate cuts in Q4; 10Y Treasury fell to 4.17% (-40bps) but long-term yields stayed relatively resilient on fiscal concerns.
- Europe: ECB cut deposit rate four times to 2% by year-end. German Bunds rose +49bps (expectations of higher public spending). French OATs +37bps (fiscal discussions). Italian BTPs broadly stable. UK gilts -9bps.
- Japan: Sharp +97bps rise to 2.07% as economy exited deflation; BoJ implemented two rate hikes and signaled gradual normalization.
- Credit spreads tightened: US spreads at tightest since 1998; European spreads compressed across both investment grade and high yield.
Exchange rates
| Currency | End of period Dec 31, 2025 | EoP change | Average 2025 | Average change |
|---|---|---|---|---|
| US Dollar | 1.17 | +13% | 1.13 | +5% |
| British Pound Sterling | 0.87 | +6% | 0.86 | +1% |
| Swiss Franc | 0.93 | -1% | 0.94 | -2% |
| Japanese Yen | 184 | +13% | 169 | +3% |
- Sharp USD depreciation driven by faster Fed easing, narrowing rate differentials, and U.S. fiscal/monetary policy concerns. EUR ended at USD 1.17 (+13%).
- EUR +6% vs. GBP (UK growth softening, BoE more accommodative); broadly stable vs. CHF (-1%); +13% vs. JPY (wide rate differentials despite BoJ normalization).
Insurance market conditions
- France: Savings insurance market +10% (premiums €192bn); Unit-linked +13%, General Account +8%; UL share 39%. Total outstanding Life insurance assets reached record €2,107bn (+6%). PER (French retirement support plan) +16% to €20bn. Protection and complementary Health market absorbed medical inflation and regulatory changes via ca. 6% average tariff increase. Natural catastrophe costs to insurers exceeded €10bn in 2025 (vs. €5bn in 2024).
- Europe: Benign P&C nat cat losses. Profitability favorable post-repricing in recent years. Strong demand for UL savings. Health: aging population, rising claims costs, price increases being implemented. Private health insurers focusing on differentiation through services, vertical integration, and digital transformation.
- Japan: Life gross written premiums -2.4% (lower foreign-currency single-premium products); UL segment growing with new entrants. P&C +4% driven by Motor and Fire price increases.
- Hong Kong: Life GWP +37%; new business +56% (GA +55%, UL +76%). P&C GWP +9.3%.
- United States (Commercial): Transition toward more competitive environment; moderating pricing in short-tail lines; persistent pressure in casualty from social inflation; overall profitability remained robust.
- Industry trends: Insurers investing in AI and data foundations to enhance efficiency and improve pricing and underwriting accuracy. Climate change, casualty trends, AI adoption, and demographic shifts generating new insurable assets, risk concentrations, and product requirements.
- Reinsurance: Additional softening projected for 2026 but profitability expected to remain strong (ROE exceeding cost of capital).
- Emerging markets:
- Asia P&C benefited from Motor (China, Philippines) and Property (Thailand, Philippines). Thailand Life new business +5% driven by Endowment products. Philippines +15% (Endowment and Corporate Solutions). Indonesia: low persistency in UL, partly offset by new Endowment and Protection launches.
- Mexico insurance market +12%; significant legislative change on VAT recoverability in October 2025 impacting Health and P&C profitability. Colombia +8%. Türkiye P&C +43% (30% inflation, volume growth in Motor and Health).
| Country | P&C ranking | P&C market share (%) | Life ranking | Life market share (%) | Comments |
|---|---|---|---|---|---|
| France | 2 | 13.2 | 6 | 7.4 |
|
| Switzerland | 1 | 13.3 | 3 | 10.0 |
|
| Germany | 4 | 5.2 | 7 | 3.4 |
|
| Belgium | 2 | 16.7 | 5 | 6.8 |
|
| United Kingdom | 6 | 6.0 | — | — |
|
| Ireland | 1 | 17.2 | — | — |
|
| Spain | 6 | 5.7 | 8 | 3.0 |
|
| Italy | 4 | 7.2 | 10 | 3.1 |
|
| Japan | 14 | 0.5 | 10 | 4.1 |
|
| Hong Kong | 2 | 9.2 | 9 | 5.0 |
|
| XL Insurance (US) | 16 | 1.5 | — | — |
|
| Thailand | 13 | 2.2 | 5 | 7.2 |
|
| Indonesia | — | — | 5 | 7.0 |
|
| Philippines | 8 | 3.0 | 6 | 20.0 (TPI) / 27.3 (NBAPE) |
|
| China | — | 0.3 | — | — |
|
| Mexico | 4 | 7.9 | 11 | 1.6 |
|
| Brazil | 11 | 2.7 | — | — |
|
| Colombia | 3 | 9.4 | 12 | 1.0 |
|
| Türkiye | 4 | 8.3 | — | — |
|
Activity and earnings indicators
GWP and other revenues
| Metric | Unit | FY2025 | FY2024 | Change (comparable) | Comments |
|---|---|---|---|---|---|
| GWP & other revenues | €m | 115,524 | 110,316 | +6.5% |
|
| Property & Casualty | €m | 58,038 | 56,514 | +5.2% |
|
| Life & Health | €m | 56,512 | 51,983 | +8.0% |
|
| o/w Life | €m | 37,499 | 34,497 | +9.5% | — |
| o/w Health | €m | 19,014 | 17,486 | +5.2% | — |
| Asset Management | €m | 875 | 1,701 | n.a. |
|
| Banking | €m | 99 | 118 | -16.2% |
|
| Net flows | €m | 5,397 | 1,483 | n.a. |
|
| Geography | Unit | FY2025 | FY2024 | Change (comparable) | Comments |
|---|---|---|---|---|---|
| GWP & other revenues | €m | 115,524 | 110,316 | +6.5% |
|
| France | €m | 30,598 | 28,996 | +5.9% | — |
| Europe | €m | 43,005 | 39,298 | +5.6% | — |
| AXA XL | €m | 19,277 | 19,383 | +3.8% | — |
| Asia, Africa & EME-LATAM | €m | 19,925 | 19,083 | +12.8% | — |
| AXA IM | €m | 875 | 1,701 | n.m. |
|
| Transversal & Other | €m | 1,844 | 1,856 | -1.3% | — |
New business performance
| Metric | Unit | FY2025 | FY2024 | Change (comparable) | Comments |
|---|---|---|---|---|---|
| PVEP | €m | 49,357 | 50,896 | -2.4% |
|
| NB CSM | €m | 2,199 | 2,169 | +2.7% |
|
| NBV | €m | 2,233 | 2,264 | -0.2% |
|
| NBV margin | % | 4.5% | 4.4% | +0.1 pt |
|
Underlying earnings by business segment
| Metric | Unit | FY2025 | FY2024 | Change (reported) | Comments |
|---|---|---|---|---|---|
| Short-term revenues | €m | 75,071 | 72,104 | +4% |
|
| Short-term technical margin | €m | 5,888 | 5,421 | +9% |
|
| P&C combined ratio | % | 90.6% | 91.0% | -0.3 pt |
|
| L&H short-term combined ratio | % | 97.2% | 97.4% | -0.2 pt |
|
| CSM release | €m | 2,954 | 2,775 | +6% |
|
| Technical experience | €m | (150) | (95) | -58% | — |
| Financial results | €m | 4,013 | 3,971 | +1% |
|
| UE before tax | €m | 11,044 | 10,700 | +3% |
|
| Income tax | €m | (2,644) | (2,662) | -1% | — |
| Underlying earnings Group share | €m | 8,368 | 8,078 | +4% |
|
| o/w P&C | €m | 5,872 | 5,510 | +7% |
|
| o/w L&H | €m | 3,501 | 3,323 | +5% |
|
| o/w Asset Management | €m | 175 | 402 | -56% |
|
| o/w Holdings | €m | (1,180) | (1,157) | -2% |
|
| CSM stock | €m | 33,253 | 33,853 | -2% |
|
Underlying earnings by geography
| Geography | Unit | FY2025 | FY2024 | Change (reported) | Comments |
|---|---|---|---|---|---|
| Underlying earnings Group share | €m | 8,368 | 8,078 | +4% |
|
| France | €m | 2,224 | 2,071 | +7% | — |
| Europe | €m | 3,486 | 3,187 | +9% | — |
| AXA XL | €m | 1,893 | 1,820 | +4% | — |
| Asia, Africa & EME-LATAM | €m | 1,493 | 1,504 | -1% | — |
| AXA IM | €m | 175 | 402 | -56% |
|
| Transversal & Other | €m | (903) | (907) | n.m. | — |
P&C combined ratio by geography
| Geography | Unit | FY2025 | FY2024 | Change | Comments |
|---|---|---|---|---|---|
| Total P&C | % | 90.6% | 91.0% | -0.3 pt |
|
| France | % | 87.5% | 86.8% | +0.7 pt | — |
| Europe | % | 90.0% | 91.0% | -1.0 pt | — |
| AXA XL | % | 89.7% | 90.2% | -0.5 pt | — |
| o/w AXA XL Insurance | % | 91.0% | 91.7% | -0.7 pt | — |
| Asia, Africa & EME-LATAM | % | 99.2% | 99.1% | +0.1 pt | — |
| Transversal & Other | % | 95.5% | 96.2% | -0.7 pt | — |
P&C combined ratio by line of business
| Line of business | Unit | FY2025 | FY2024 | Change | Comments |
|---|---|---|---|---|---|
| Total P&C | % | 90.6% | 91.0% | -0.3 pt | — |
| Commercial lines | % | 90.7% | 91.1% | -0.4 pt |
|
| Personal lines | % | 92.8% | 93.9% | -1.1 pt |
|
| AXA XL Reinsurance | % | 81.4% | 79.7% | +1.7 pt |
|
Life & Health underlying earnings
| Metric | Unit | FY2025 | FY2024 | Change (reported) | Comments |
|---|---|---|---|---|---|
| Short-term revenues | €m | 17,416 | 16,207 | +7% |
|
| Short-term combined ratio | % | 97.2% | 97.4% | -0.2 pt |
|
| Short-term technical margin | €m | 479 | 415 | +15% |
|
| CSM release | €m | 2,954 | 2,775 | +6% |
|
| Technical experience | €m | (150) | (95) | -58% |
|
| Financial result | €m | 946 | 975 | -3% |
|
| UE before tax | €m | 4,229 | 4,070 | +4% |
|
| Income tax | €m | (800) | (874) | +8% |
|
| UE Group share | €m | 3,501 | 3,323 | +5% |
|
| CSM stock | €m | 32,991 | 33,571 | -2% |
|
Net income
| Metric | Unit | FY2025 | FY2024 | Change (reported) | Comments |
|---|---|---|---|---|---|
| Underlying earnings Group share | €m | 8,368 | 8,078 | +4% |
|
| Net realized capital gains & losses | €m | 138 | 195 | -29% |
|
| Fair value of funds & derivatives | €m | (813) | 83 | n.m. |
|
| Amortization of intangibles | €m | (86) | (131) | +34% |
|
| Integration & restructuring costs | €m | (197) | (240) | +18% |
|
| Exceptional items | €m | 2,386 | (99) | n.m. |
|
| Net income Group share | €m | 9,797 | 7,886 | +24% |
|
| Item | Unit | Amount | Comments |
|---|---|---|---|
| Opening (Dec 31, 2024) | €m | 49,943 | — |
| Net income for the period | €m | +9,797 | — |
| Dividends | €m | (4,629) | — |
| Paid-in capital | €m | (4,863) |
|
| Impact of currency fluctuations | €m | (3,549) |
|
| Fair value recorded in shareholders' equity | €m | +1,282 | — |
| OCI related to invested assets | €m | (4,161) | — |
| OCI related to (re)insurance contracts | €m | +5,443 | — |
| OCI defined benefit plans | €m | (350) | — |
| Treasury shares | €m | (97) | — |
| Realized gains on equity through retained earnings | €m | +111 | — |
| Undated subordinated debt (incl. interest) | €m | (300) | — |
| Other | €m | (174) | — |
| Closing (Dec 31, 2025) | €m | 47,171 |
|
Solvency information
| Metric | Unit | FY2025 | FY2024 | Change | Comments |
|---|---|---|---|---|---|
| Eligible Own Funds | €bn | 56.4 | 55.9 | +0.5 | — |
| Solvency II ratio | % | 224% | 216% | +8 pts |
|
| Metric | Unit | FY2025 | FY2024 | Change | Comments |
|---|---|---|---|---|---|
| Weighted avg. shares (fully diluted) | m shares | 2,124 | 2,197 | -3% |
|
| Underlying EPS (fully diluted) | €/share | 3.86 | 3.59 | +8% |
|
| Net income EPS (fully diluted) | €/share | 4.53 | 3.50 | +30% |
|
| Underlying ROE | % | 16.0% | 15.2% | +0.8 pts |
|
| Net income ROE | % | 18.8% | 14.8% | +3.9 pts |
|
| Avg. adj. shareholders' equity | €bn | 51.3 | 51.8 | -1% |
|
| Debt gearing | — | — | — | — |
|
Outlook
- Final year of 2024-2026 "Unlock the Future" plan. Management confident in achieving main financial targets, underpinned by profitable organic growth, scaling technical capabilities, and driving operational efficiency through reinforced cost management.
- P&C: Pricing remains favorable in Retail and SME/Mid-market; expect continued earn-through of higher pricing and underwriting actions. AXA XL: disciplined cycle management and capital allocation, growing where returns exceed cost of capital. Normalized nat cat load guidance: ca. 4.5 points of combined ratio for 2026.
- Life & Health: Earnings growth expected from short-term business (disciplined pricing and claims management). Long-term business strategy focused on rejuvenating sales, improving persistency, and driving positive net flows to grow CSM over time.
- Holdings: 2026 results expected at a similar level to 2025.
- Financial targets:
- Underlying EPS growth at the upper end of 6-8% CAGR range for both the 2023-2026E plan period and for 2026.
- Underlying ROE between 14-16% over 2024-2026E.
- Cumulative organic cash upstream in excess of €21bn for 2024-2026.
- Capital management policy: 75% total payout ratio (60% dividend payout + 15% annual share buy-backs). Proposed DPS in a given year expected to be at least equal to prior year's DPS.